17 % des patients ont été placé d'abord sous HUMIRAÒ, qui a ensuite été switché par du REMICADEÒ. Et 13 % des patients sont passés du REMICADEÒ à l'HUMIRAÒ. (Figure 56) De même 13 % ont arrêté le traitement par anti-TNF soit à la demande du médecin car les patients étaient totalement asymptomatiques avec des lésions complètement cicatrisées ,
la majorité des patients (50 %) sont stables sous cette biothérapie et continuent encore à l'utiliser aujourd'hui (« biothérapie en cours/non switch ») ,
seul un patient a été traité par biosimilaire : l'INFLECTRAÒ, et il a présenté exactement les mêmes effets indésirables (réaction post-injection) que les patients BIBLIOGRAPHIE 1, INSERM. Maladies inflammatoires chroniques de l'intestin (MICI) [Internet], 2016. ,
Disponible sur: https://www.vulgaris-medical.com/encyclopedie-medicale/incidence 6 ,
Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data, Inflammatory Bowel Diseases, vol.12, issue.3, p.21826, 2006. ,
DOI : 10.1053/gast.2003.50021
URL : https://hal.archives-ouvertes.fr/hal-00466309
Crohn's disease: does race matter? The Mid-Atlantic Crohn's Disease Study Group, Am J Gastroenterol. févr, vol.95, issue.2, p.47983, 2000. ,
Inflammatory bowel disease in spouses and their offspring, Gastroenterology, vol.120, issue.4, 2001. ,
DOI : 10.1053/gast.2001.22574
Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice Active and passive smoking in childhood is related to the development of inflammatory bowel disease, Gastroenterology. août Inflamm Bowel Dis. avr, vol.15313, issue.24, pp.55065-144318, 2007. ,
The Link between the Appendix and Ulcerative Colitis: Clinical Relevance and Potential Immunological Mechanisms Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review, ):27786. 17. Lowenfels AB, Maisonneuve P. Appendectomy and protection against ulcerative colitis, pp.1639-16223, 2001. ,
Effects of appendicectomy on the course of ulcerative colitis Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease, Gut. déc Gut. mai, vol.5163, issue.195, p.803777684, 2002. ,
Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis?, Journal of Gastroenterology and Hepatology, vol.23, issue.2, p.1794801, 2008. ,
DOI : 10.3748/wjg.v12.i37.5941
Review article: diet and inflammatory bowel disease - epidemiology and treatment, Alimentary Pharmacology & Therapeutics, vol.126, issue.Suppl. 10, p.99112, 2009. ,
DOI : 10.1080/00365520510023729
Re: « The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis ». Response to Cornish et al Review article: mechanisms of initiation and perpetuation of gut inflammation by stress Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission, Gastroenterology. mai Villafruela Cives M Am J Gastroenterol. févr Aliment Pharmacol Ther. déc Am J Gastroenterol. mai, vol.1261041695, issue.62125, pp.150417-235345, 2000. ,
Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study, LR. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders, pp.118591177582-31, 2008. ,
Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial, Gastroenterology, vol.128, issue.4, pp.23755-3282532, 2004. ,
DOI : 10.1053/j.gastro.2005.01.005
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines, Nature. 1 janv, vol.391, issue.6662, pp.826-862, 1998. ,
Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor, ):91222. 38. Kaser A, pp.74356-3926259918, 1984. ,
Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis Colonic sulfide in pathogenesis and treatment of ulcerative colitis, ):15719. 44. Hausmann M, pp.28191-4247986, 1997. ,
Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis, Dig Dis Sci. sept, vol.49, issue.9, pp.143843-143890, 2004. ,
Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology, Nature, vol.148, issue.7293, 2010. ,
DOI : 10.1038/nature08949
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796764/pdf
Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity, Am J Gastroenterol. sept, vol.94, issue.9, 1999. ,
Interleukin- 13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution, Gastroenterology. août Feagan BG, vol.129, issue.54, p.55064, 2005. ,
Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort, août J Crohns Colitis. 1 oct, vol.36911, issue.810, pp.699710-5512004, 2013. ,
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders PET/MRI for evaluating subclinical inflammation of ulcerative colitis, Accueil Pro | SFED [Internet]. [cité 4 nov 2017]. Disponible sur Rectocolite hémorragique et cancer colorectal (accés libre) [Internet], 2007. ,
Disponible sur: https://www.afa.asso.fr/article/archives- rectocolite-hemorragique-et-cancer-colorectal.html 61, Br Med J. 11 janv, vol.1, issue.5375, p.8992, 1964. ,
Disponible sur, 2017. ,
Natural history of Crohn's disease: comparison between childhood-and adult-onset disease, Inflamm Bowel Dis. juin, vol.16, issue.6, p.95361, 2010. ,
The safety of mesalamine in human pregnancy: a prospective controlled cohort study, Ceska Gynekol. Diav-Citrin O, vol.82, issue.65, p.10816, 2017. ,
A severe neonatal lymphopenia associated with administration of azathioprine to the mother in a context of Crohn's disease, CRAT -Centre de référence sur les agents tératogènes chez la femme enceinte [Internet]. [cité 4 nov 2017]. Disponible sur, pp.238-66, 1998. ,
Oral contraceptives, reproductive factors and risk of inflammatory bowel disease, Gut, vol.57, issue.Suppl 3, 2013. ,
DOI : 10.1097/NNR.0b013e31818bf38b
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol. sept, vol.71110, issue.9, p.132438, 2015. ,
Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus, Gastroenterology, vol.148, issue.5, pp.10351058-10351061, 2015. ,
DOI : 10.1053/j.gastro.2015.03.001
Disponible sur: https, Wikipédia [Internet]. 2017 ,
The safety of non-biological treatments in Ulcerative Colitis, Expert Opinion on Drug Safety, vol.366, issue.4, 2017. ,
DOI : 10.1016/j.cger.2013.10.007
Anti-TNF therapy: past, present and future):5562. 88. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies, Int Immunol. janv Nat Rev Rheumatol. janv, vol.2712, issue.11, p.4962, 2015. ,
DOI : 10.1093/intimm/dxu102
URL : https://academic.oup.com/intimm/article-pdf/27/1/55/9723550/dxu102.pdf
Disponible sur: https://pharmacomedicale.org/medicaments/par-specialites/item/anti-tnf-alpha 90. Flamant M, Roblin X. Could therapeutic drug monitoring of anti-TNF-? be useful to consider a de-escalation of treatment? Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists, Expert Opin Biol Ther. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. févr, vol.1515, issue.112, pp.229239-229244, 2015. ,
The safety of vedolizumab for ulcerative colitis and Crohn's disease, ):83951. 93. Wyant T, Fedyk E, Abhyankar B. An Overview of the Mechanism of Action of the, 2017. ,
DOI : 10.1136/gutjnl-2015-311079
When Not to Pouch: Important Considerations for Patient Selection for Ileal Pouch-Anal Anastomosis Alves A, Penna C. Traitement chirurgical d'une rectocolite hémorragique chez une jeune femme, Gastroenterol Hepatol. août, vol.13, issue.8, pp.46675-97, 2017. ,
European evidence-based Consensus on the management of ulcerative colitis: Special situations, Journal of Crohn's and Colitis, vol.23, issue.Suppl II ,
DOI : 10.1111/j.1365-2036.2006.02761.x
Pouchitis: What Every Gastroenterologist Needs to Know, Clinical Gastroenterology and Hepatology, vol.11, issue.12, p.153849, 2013. ,
DOI : 10.1016/j.cgh.2013.03.033
A Randomized Clinical Trial of Ciprofloxacin and Metronidazole to Treat Acute Pouchitis, Inflammatory Bowel Diseases, vol.59, issue.4, p.3015, 2001. ,
DOI : 10.1136/ard.59.7.565
Cumulative Failure Rate of Ileal Pouch-Anal Anastomosis and Quality of Life After Failure, Diseases of the Colon & Rectum, vol.45, issue.10, p.128994, 2002. ,
DOI : 10.1007/s10350-004-6412-9
Quality of Life after colectomy due to ulcerative colitis], Laeknabladid. nov, vol.102, issue.11, p.4829, 2016. ,
Les probiotiques, des outils thérapeutiques pour moduler les effets biologiques de la flore intestinale: une introductionAn introduction to probiotics as potential therapeutic tools. Obésité. 1 sept, 2007. ,
Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier, World Journal of Gastroenterology, vol.20, issue.28, p.946875, 2014. ,
DOI : 10.1038/ajg.2008.118
Influences of the colonic microbiome on the mucous gel layer in ulcerative colitis, Gut Microbes, vol.42, issue.3, p.27785, 2014. ,
DOI : 10.3201/eid0602.000210
Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN), BMC Complementary and Alternative Medicine, vol.100, issue.Suppl 3, p.13, 2010. ,
DOI : 10.1111/j.1572-0241.2005.40641.x
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial, The Lancet, vol.354, issue.9179 ,
DOI : 10.1016/S0140-6736(98)06343-0
Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study, Inflammatory Bowel Diseases, vol.121, issue.5, p.7608, 2009. ,
DOI : 10.1053/gast.2001.27224
The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.7, issue.11, pp.12021209-1209, 2009. ,
DOI : 10.1016/j.cgh.2009.07.016
Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis, The American Journal of Gastroenterology, vol.10, issue.2, p.43743, 2009. ,
DOI : 10.1053/j.gastro.2003.11.019
Lowdose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis, Med Sci Monit Int Med J Exp Clin Res. nov, vol.10, issue.11, pp.126-131, 2004. ,
Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study, The American Journal of Gastroenterology, vol.17, issue.10, p.221827, 2010. ,
DOI : 10.1038/nri2515
Probiotics and prebiotics in ulcerative colitis, Best Practice & Research Clinical Gastroenterology, vol.30, issue.1, 2016. ,
DOI : 10.1016/j.bpg.2016.02.005
Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis, PLOS ONE, vol.105, issue.43, p.157259, 2016. ,
DOI : 10.1371/journal.pone.0157259.s005
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial, Gastroenterology, vol.149, issue.1, pp.102109-102115, 2015. ,
DOI : 10.1053/j.gastro.2015.04.001
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial, The Lancet, vol.389, issue.10075, 2017. ,
DOI : 10.1016/S0140-6736(17)30182-4
Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease, Annals of the New York Academy of Sciences, vol.60, issue.Suppl. 1, p.3748, 2017. ,
DOI : 10.1021/jf300441p
Oral administration of curcumin attenuates visceral hyperalgesia through inhibiting phosphorylation of TRPV1 in rat model of ulcerative colitis, Molecular Pain, vol.14, p.1744806917726416, 2017. ,
DOI : 10.1111/j.1469-7793.2001.00813.x
The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study, The American Journal of Gastroenterology, vol.11, issue.3, p.111622, 2001. ,
DOI : 10.1016/0049-0172(91)90011-N
Crohn???s disease: Another unusual manifestation responded to metronidazole, Journal of the Saudi Society of Dermatology & Dermatologic Surgery, vol.15, issue.2, p.679, 2011. ,
DOI : 10.1016/j.jssdds.2011.04.002
URL : https://doi.org/10.1016/j.jssdds.2011.04.002
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France, Seminars in Arthritis and Rheumatism, 2017. ,
DOI : 10.1016/j.semarthrit.2017.10.002